CTX Platforms

Company Overview

Snapshot

Founded in March 2018 by Omer Porat and Hagay Shmuely, CTX Platforms operated with 1–10 employees. The company focused on developing a disruptive targeted technology for cancer therapy and diagnostics, holding one patent in this field. The company ceased operations in July 2023.

Business overview

CTX Platforms is a biotechnology company specializing in health tech and life sciences, with a focus on pharmaceuticals, diagnostics, and biopharmaceutical solutions. The company developed a theranostic system designed for imaging and treating brain cancers and other non-CNS tumors. This technology utilizes magnetic nanoparticles and magnetic fields heating to destroy cancer cells, aiming to provide a non-invasive treatment option. Operating in the United States, CTX Platforms targets the healthcare and life sciences markets, including patients and providers, with its B2B business model.

Company Intelligence Q&A

What is the primary focus of CTX Platforms?

CTX Platforms focuses on developing a disruptive targeted technology for the imaging and treatment of brain cancers and other non-CNS tumors, utilizing magnetic nanoparticles and magnetic fields.

When was CTX Platforms founded and by whom?

CTX Platforms was founded in March 2018 by Omer Porat and Hagay Shmuely.

What is the current status of CTX Platforms?

CTX Platforms ceased to operate in July 2023.

What technology does CTX Platforms employ for cancer treatment?

CTX Platforms develops a theranostic system that uses sophisticated delivery of magnetic nanoparticles and induction of focal heat via non-invasive magnetic fields to destroy cancer cells.

In which markets does CTX Platforms operate?

CTX Platforms operates in the United States, targeting the healthcare and life sciences sectors.